Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network E4512): a phase 3 trial
It is suggested that crizotinib should not be recommended as an adjuvant therapy for patients with resected, early-stage ALK-positive NSCLC and that crizotinib should not be recommended as an adjuvant therapy for patients with resected ALK-positive NSCLC.